StageBio, a provider of GLP-compliant histology, pathology, image analysis and archiving services for both preclinical and clinical research, has appointed David Bruning as Chief Executive Officer.
 
Having served on the StageBio Board of Directors for the past five years in addition to previously being a longstanding customer of StageBio, Bruning possesses a deep understanding of the company, its strategic priorities and the evolving needs of its customers. Bruning brings over 25 years of leadership experience within product-based and preclinical testing services companies, including BioReliance (a business of MilliporeSigma / Merck KGaA of Darmstadt, Germany) and Life Technologies (a division of Invitrogen).
 
He holds a B.S. in Biology from the California Institute of Technology and an M.B.A. from Loyola College.
 
“I’m grateful for the opportunity to lead StageBio in its next phase of growth,” Bruning commented. “We have a talented and innovative team across our sites in North America and Europe dedicated to delivering superior service and scientific rigor to our customers throughout the biopharmaceutical, medical device, and contract research industries. Together as a global team, we are well-positioned to further build on our foundation as a leading histopathology provider to enable the success of our customers.”
 
Melanie Fan, Principal, Ampersand Capital Partners and member of the StageBio Board of Directors added, “We are thrilled to have David transition into this role, after having been a valuable member of the Board the last five years. David’s understanding of the business and its customers, coupled with his industry expertise, positions him for success in driving continuous growth for StageBio in 2024 and beyond.”